Paclitaxel Poliglumex
N/A
Report date: 2026/04/12 20:00:13
NME
Base Information
Drug NamePaclitaxel Poliglumex
Drug Alias Name +[9]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[75]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[73]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A
Develop Information
Active CompaniesGog Foundation IncBristol Myers Squibb SrlcompanyUniversity of Texas Southwestern Medical Center +[31]
Inactive CompaniesHanmi Pharmaceutical Co LtdDana-Farber Cancer InstituteSwedish Orphan Biovitrum (Sobi) +[47]
Active Indications +[34]
Inactive Indications +[41]